Prodigiosin as an antibiofilm agent against multidrug-resistant .
Jing Yan, Qi Yin, Hao Nie, Jinyou Liang, Xiang-Ru Liu, Yingli Li, Hong Xiao
Author Information
Jing Yan: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, PR China.
Qi Yin: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, PR China.
Hao Nie: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, PR China.
Jinyou Liang: Shenzhen Key Laboratory of Marine Bioresource & Eco-environmental Science, Shenzhen Engineering Laboratory for Marine Algal Biotechnology, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, PR China.
Xiang-Ru Liu: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, PR China.
Yingli Li: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, PR China.
Hong Xiao: Department of Health Laboratory Technology, School of Public Health, Chongqing Medical University, Chongqing, PR China.
is known for forming bacterial biofilms that confer increased antimicrobial resistance. Combining antibiotics with antibiofilm agents is an alternative approach, but the antibiofilm ability of prodigiosin (PG), a potential antibiotic synergist, against antimicrobial-resistant (AMR) remains to be understood. The antibiofilm activity of PG against 29 clinical AMR strains was evaluated using crystal violet staining, and its synergistic effects with vancomycin (VAN) was confirmed using the checkerboard test. The viability and metabolic activity of biofilms and planktonic cells were also assessed. The results revealed that PG exhibited promising inhibitory activity against biofilm formation and synergistic activity with VAN. It effectively reduced the metabolic activity of biofilms and suppressed the production of exopolysaccharides, which might be attributed to the downregulation of biofilm-related genes such as , , and . These findings suggest that PG could be used as a preventive coating or adjuvant against biofilms in clinical settings.
